IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30

被引：0
|
作者：
Vaag, A.
Leiter, L. A.
Franek, E.
Weng, J.
Damci, T.
Munoz Torres, M.
Donnet, J. -P.
Endahl, L.
Skjoth, T.
Niskanen, L.
机构：
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1040
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [1] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes
    Hirsch, I.
    Franek, E.
    Courreges, J. P.
    Mersebach, H.
    Dykiel, P.
    Bode, B. W.
    [J]. DIABETOLOGIA, 2011, 54 : S427 - S427
  • [2] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [3] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    [J]. DIABETOLOGIA, 2018, 61 : S410 - S411
  • [4] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [5] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [6] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    [J]. DIABETES, 2018, 67
  • [7] The Study on the Clinical Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp)
    Kusama, Minoru
    [J]. DIABETES, 2018, 67
  • [8] Biphasic insulin aspart and biphasic human insulin in type 2 diabetes: A comparison
    Jacobsen, LV
    Bell, PM
    McSorely, P
    Kristensen, A
    [J]. DIABETES, 2000, 49 : A112 - A112
  • [9] Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)
    Kalra, Sanjay
    Atkin, Stephen
    Cervera, Antonio
    Das, Ashok Kumar
    Demir, Ozgur
    Demir, Tevfik
    Fariduddin, Md.
    Khoa Tuan Vo
    Ku, Bon Jeong
    Kumar, Ajay
    Latif, Zafar A.
    Malek, Rachid
    Matawaran, Bien J.
    Mehta, Roopa
    Nam Quang Tran
    Panelo, Araceli
    Ruder, Sundeep
    Saldana, Joel Rodriquez
    Shaikh, Khalid A.
    Shakya, Amit
    Shrestha, Dina
    Unnikrishnan, A. G.
    [J]. ADVANCES IN THERAPY, 2018, 35 (07) : 928 - 936
  • [10] Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)
    Sanjay Kalra
    Stephen Atkin
    Antonio Cervera
    Ashok Kumar Das
    Ozgur Demir
    Tevfik Demir
    Md. Fariduddin
    Khoa Tuan Vo
    Bon Jeong Ku
    Ajay Kumar
    Zafar A. Latif
    Rachid Malek
    Bien J. Matawaran
    Roopa Mehta
    Nam Quang Tran
    Araceli Panelo
    Sundeep Ruder
    Joel Rodriquez Saldana
    Khalid A. Shaikh
    Amit Shakya
    Dina Shrestha
    A. G. Unnikrishnan
    [J]. Advances in Therapy, 2018, 35 : 928 - 936
12345